Clinical Trials Directory

Trials / Unknown

UnknownNCT01637506

Urine and Stool Analysis in Kidney Stone Disease

Correlation Between Excretion Metabolites in Urine and Bacterial Microflora in Patients With Urinary Stone Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
University of British Columbia · Academic / Other
Sex
All
Age
19 Years – 90 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to add to the investigators' quest to understanding stone disease, by evaluating the metabolites excretion in urine and its relation to microflora present in the stool.

Detailed description

Kidney stones affect up to 10% of the Canadian population and can lead to pain, hospitalization, lost of time at work, and surgery. Approximately 80% of stones consist of calcium and oxalate, of which both components come from diet and normal bodily processes. Individuals who have high levels of oxalate in their urine have a greater tendency to generate stones. One recommendation is to reduce their intake of oxalate-containing foods, but many healthy foods contain oxalate, and an oxalate-free diet is unpalatable and difficult to achieve. Some patients, despite reducing their oxalate intake, still have high amounts in the urine. Intestinal metabolism is largely affected by the state and composition of the intestinal bacterial flora, with several metabolic diseases being linked to a disrupted "normal" intestinal flora. The investigators believe that calcium oxalate stone disease as well as high urinary levels of oxalate (hyperoxaluria) are triggered by inefficient oxalate metabolism in the intestine, which is linked to a "disrupted" intestinal bacterial flora that lacks certain key components such as O. formigenes. The long-term purpose of this study is therefore, to determine the effect of replenishing the intestinal flora of patients with that of "normal" controls, thereby re-introducing a balanced environment that will lead to the re-establishment of normal metabolic functions and a decrease in urinary oxalate levels and hopefully lower incidence of stone disease.

Conditions

Timeline

Start date
2012-07-01
Primary completion
2022-12-01
Completion
2022-12-01
First posted
2012-07-11
Last updated
2022-11-02

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT01637506. Inclusion in this directory is not an endorsement.